These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 21638088

  • 41. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [Abstract] [Full Text] [Related]

  • 42. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients.
    Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, Sameer Aga S.
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [Abstract] [Full Text] [Related]

  • 43. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 44. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.
    Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS, Choi JR.
    Head Neck; 2010 Apr; 32(4):490-8. PubMed ID: 19672964
    [Abstract] [Full Text] [Related]

  • 45. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P, Brunelli C, Rossi ED, Lanza P, Martini M, Musarra T, Lombardi CP, Pontecorvi A, Fadda G.
    Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
    [Abstract] [Full Text] [Related]

  • 46. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.
    Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG.
    Am J Clin Pathol; 2015 Jan; 143(1):89-99. PubMed ID: 25511147
    [Abstract] [Full Text] [Related]

  • 47. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis.
    Parker KG, White MG, Cipriani NA.
    Head Neck Pathol; 2020 Dec; 14(4):1067-1079. PubMed ID: 32358715
    [Abstract] [Full Text] [Related]

  • 48. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
    Adackapara CA, Sholl LM, Barletta JA, Hornick JL.
    Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
    [Abstract] [Full Text] [Related]

  • 49. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, De Braekeleer M, Le Marechal C, Marcorelles P.
    Diagn Pathol; 2015 Jul 25; 10():121. PubMed ID: 26204954
    [Abstract] [Full Text] [Related]

  • 50. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L.
    Anticancer Res; 2010 Sep 25; 30(9):3267-72. PubMed ID: 20944096
    [Abstract] [Full Text] [Related]

  • 51. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.
    Am J Surg Pathol; 2014 Sep 25; 38(9):1235-41. PubMed ID: 24832158
    [Abstract] [Full Text] [Related]

  • 52. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    Schirosi L, Strippoli S, Gaudio F, Graziano G, Popescu O, Guida M, Simone G, Mangia A.
    BMC Cancer; 2016 Nov 18; 16(1):905. PubMed ID: 27863476
    [Abstract] [Full Text] [Related]

  • 53. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.
    Marin C, Beauchet A, Capper D, Zimmermann U, Julié C, Ilie M, Saiag P, von Deimling A, Hofman P, Emile JF.
    Arch Pathol Lab Med; 2014 Jan 18; 138(1):71-5. PubMed ID: 23651150
    [Abstract] [Full Text] [Related]

  • 54. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W.
    Ann Surg Oncol; 2009 Feb 18; 16(2):240-5. PubMed ID: 19034577
    [Abstract] [Full Text] [Related]

  • 55. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.
    Hum Pathol; 2005 May 18; 36(5):486-93. PubMed ID: 15948115
    [Abstract] [Full Text] [Related]

  • 56. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T.
    Anticancer Res; 2007 May 18; 27(5B):3645-9. PubMed ID: 17972530
    [Abstract] [Full Text] [Related]

  • 57. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

  • 58. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
    Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares AH, Friedlander P, Miccoli P, Kandil E.
    Surgery; 2017 Apr 01; 161(4):1122-1128. PubMed ID: 27919446
    [Abstract] [Full Text] [Related]

  • 59. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
    Atik E, Guray M, Gunesacar R, Ozgur T, Canda T.
    Indian J Cancer; 2014 Apr 01; 51(1):63-8. PubMed ID: 24947099
    [Abstract] [Full Text] [Related]

  • 60. Lack of BRAF V600E protein expression in primary central nervous system lymphoma.
    Berghoff AS, Capper D, Preusser M.
    Appl Immunohistochem Mol Morphol; 2013 Jul 01; 21(4):351-3. PubMed ID: 23235345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.